Repaglinide/troglitazone combination therapy: Improved glycemic control in type 2 diabetes

Diabetes Care

Volumn 23, Issue 7, 2000, Pages 979-983

  Raskin, Philip ^a   Jovanovic, Lois ^b   Berger, Sheldon ^c   Schwartz, Sherwyn ^d   Woo, Vincent ^f   Ratner, Robert ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Sansum Medical Research Institute   (United States)

^c RADIANT RESEARCH   (United States)

^d Diabetes and Glandular Disease Clinic   (United States)

^e Medlantic Clinical Research Center   (United States)

^f UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; REPAGLINIDE; TROGLITAZONE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

EID: 0033927081     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.7.979     Document Type: Article

References (10)

1. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H: Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 22:119-124, 1999
2. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabet Med 13:365-370, 1996
3. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H: Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 17:224-231, 1991
4. Ratner RE: Repaglinide therapy in the treatment of type 2 diabetes. Today's Ther Trends 17:57-66, 1999
5. Fuhlendorf J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47:345-351, 1998
6. Hulin B: New hypoglycemic agents. Prog Med Chem 31:1-58, 1994
7. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359, 1997
8. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
9. Andersson DKG, Svardsudd K: Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 18:1534-1543, 1995
10. Medical Economics Company: Repaglinide (Prandin™) product labeling. In Physicians' Desk Reference. 53rd ed. Montvale, NJ, 1999, p. 2107-2110